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http://dx.doi.org/10.1016/j.pedneo.2Background/purpose: The purpose of this study was to evaluate the effectiveness and tolera-
bility of aripiprazole in short-term treatment of children and adolescents with tic disorder (TD).
Methods: This was a 14-week, prospective, open-label flexible dose trial of aripiprazole. We
enrolled patients with TD aged between 4 years and 18 years. They received aripiprazole (dose:
2.5 mg/day) initially, which was then adjusted according to clinical response. The severity was
assessed by the Yale Global Tic Severity Score (YGTSS) at 0, 2, 6, 10, and 14 weeks. The linear
mixed models were used for evaluation of the YGTSSs at each follow-up, which were compared
with baseline scores.
Results: Eighty-one patients were enrolled in this study. Nine patients withdrew from the study
with complaints of adverse side effects. Of the remaining 72 patients, 15 patients discontinued
medications prematurely due to being free of symptoms for over 2 weeks. Two patients discon-
tinued medications due to no significant improvement. The mean scores had significantly
decreased since the 2nd week (p< 0.01). The mean reduction was 51.0% in the motor tic scores,
67.1% in the vocal tic scores, and 70.0% in the total YGTSSs. The common adverse effects were
sedation (32.1%) and increased appetite (22.2%). A slight increase in average body weight was
noted, from 32.7 to 33.7 kg (þ1.0 kg, p < 0.05).t of Pediatrics, Mackay Memorial Hospital Taitung Branch, Mackay Memorial Hospital, 1, Lane 303,
il.com (Y.-L. Huang).
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Aripiprazole in treatment of tic disorder 49Conclusion: Aripiprazole is effective for short-term treatment of TD, especially vocal tics, in
children and adolescents with mild adverse effects. However, further double-blind trials against
placebo or other medications are needed to verify the efficacy of aripiprazole in the pharma-
cotherapy of TD.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Tic disorder (TD) is a common childhood-onset neuropsy-
chiatric disorder, characterized by sudden, fast, repetitive,
nonrhythmic, and stereotyped motor movements and/or
phonic productions. The diagnosis is based on the Diag-
nostic and Statistical Manual of Mental Disorders, 4th
edition, Text Revision (DSM-IV-TR) criteria (published by the
American Psychiatric Association in 2000). Based on the
type and duration of tics, it is classified as transient TD,
chronic TD, and Tourette syndrome (TS). Common comor-
bidities of TDs are attention deficit hyperactivity disorder
(ADHD), obsessive-compulsive disorder, oppositional
defiant disorder, and other mood disorders.1
Although the exact pathophysiology of TD remains un-
clear, potent dopamine D2 antagonist is the major treat-
ment of tics.2 Haloperidol and pimozide are the only
formally approved medications currently used to treat TD
and the drugs can reduce symptoms in approximately 66%
and 60% of patients, respectively. However, adverse ef-
fects, such as acute dystonic reactions, akathisia, tardive
dyskinesia, extrapyramidal syndrome (EPS), and prolonged
QTc, are bothersome.2e5
Aripiprazole, an atypical antipsychotic medication, has a
unique pharmacology, and it plays the role of a dop-
amineeserotonin system stabilizer rather than the dop-
amineeserotonin antagonist. It is a partial agonist of D2
receptors, but it also acts as an antagonist in the presence
of excess dopamine. In addition, it is also an agonist of 5-
HT1A receptors and an antagonist of 5-HT2A receptors.
Theoretically, it might have a lower potential for EPS than
other more traditional antipsychotics.6
The purpose of this study was to evaluate the short-term
effects and tolerability of aripiprazole in children and ad-
olescents with TD.2. Patients and Methods
This study was a 14-week, prospective, open-label flexible
dose trial in children and adolescents with TD receiving
monotherapy with aripiprazole.
We enrolled patients between 4 and 18 years of age with
transient TD, chronic TD or TS, and symptoms of TD that
were severe enough to influence social function, self-
esteem, or quality of daily life. Our protocol was
approved by the Institutional Review Board. Diagnosis was
established based on DSM-IV-TR at the outpatient clinic of
the Mackay Memorial Hospital. The patients had been free
from medications for tics for at least 3 months before entry.
Exclusion criteria were (1) mental retardation; (2) seizureactivity; (3) obsessive-compulsive disorder, autism, and
other psychiatric illness, except ADHD; (4) combined use of
other psychostimulants, mood stabilizers, or anticonvul-
sants; and (5) allergy to any neuroleptics.
All patients received 2.5 mg aripiprazole (Otsuka Phar-
maceutical Co. Tokushima, Japan) at bedtime initially. We
offered each patient specific pill master to cut pills into
pieces. At each visit, the clinicians adjusted the dose ac-
cording to clinical response, severity of disease, and
adverse effects. The evaluation of adverse effects depen-
ded on patients’ and their parents’ subjective complaints.
If adverse effects were not tolerated, aripiprazole was
discontinued immediately. If participants were completely
symptom free for more than 2 weeks under 2.5 mg/day
aripiprazole, early discontinuation of medications was
considered.
We used the Yale Global Tic Severity Score (YGTSS),
which is widely used with excellent interactive reliability,
to evaluate the severity of the disease. This scale consisted
of three scores, namely, motor tic (0e25), vocal tic (0e25),
and total YGTSSs (sum of motor tic scores, vocal tic scores,
and impairment scores; 0e100). The ratings for motor and
vocal tics included number, frequency, intensity,
complexity, and interference. We rated the YGTSSs and
checked body weight of the patients at their first clinical
visit as the baseline and then at the 2nd, 6th, 10th, and
14th weeks. The YGTSS was calculated by the same clini-
cian to avoid personal bias.
2.1. Statistical analyses
The results of YGTSSs (including motor tic, vocal tic, and
total YGTSSs) were recorded as mean  standard deviation
(SD). The linear mixed models were used for the evaluation
of repeated measures for the YGTSSs at each follow-up
compared with baseline. The linear mixed model was
adjusted for age, gender, diagnosis, and dose. The average
of individual body weights at baseline and end point was
compared using a paired t test. A p value < 0.05 was taken
to be significant. All statistical analyses were performed
using SPSS version 17.0 software (SPSS Inc., Chicago, IL,
USA).3. Results
The baseline demographics and diagnosis of the eligible
patients (n Z 81) are listed in Table 1. Nine patients were
unable to complete the study protocol due to adverse ef-
fects, including sedation (n Z 6), gastrointestinal upset
(n Z 2), change of appetite (n Z 2), hand tremor (n Z 1),
Table 1 Descriptive data for the 81 patients with tic
disorder treated with aripiprazole.
Variable Value
Age (y, mean  SD) 8.3  3.4
Gender
Male 60 (74.1)
Female 21 (25.9)
Type of tic disorder
Tourette syndrome 25 (30.9)
Chronic tic disorder 3 (3.7)
Transient tic disorder 53 (65.4)
Data are presented as n (%).
SD Z standard deviation.
50 C.-S. Ho et aldizziness (n Z 1), and quietness (n Z 1). The discontinu-
ation rate for this study was 11.1%.
Fifty-five patients completed the trial, and 15 patients
discontinued aripiprazole before 14 weeks due to being
completely symptom free for more than 2 weeks when
treated with aripiprazole (2.5 mg/day). Another two pa-
tients discontinued aripiprazole at the 6th and 10th weeks
due to no significant improvement. The mean motor tic
scores were 11.03  5.04, 7.61  5.70, 6.63  5.47,
4.90  5.39, and 5.40  5.42 at baseline and at weeks 2, 6,
10, and 14, respectively. The mean vocal tic scores were
8.51  6.40, 5.59  5.75, 4.52  5.40, 3.61  4.86, and
2.80  4.33 at baseline and at weeks 2, 6, 10, and 14,
respectively. The mean impairment scores were
10.56  3.71, 3.71  5.70, 2.09  4.10, 0.82  2.77, and
0.74  2.64 at baseline and at weeks 2, 6, 10, and 14,
respectively. The mean total YGTSSs were 30.10  7.35,
16.91  11.45, 13.24  10.98, 9.33  9.04, and 9.04  8.45
at baseline and at weeks 2, 6, 10, and 14, respectively. A
significant reduction had been observed since the 2nd week
(Table 2). The mean scores had significantly decreased
since the 2nd week (p < 0.01). Overall, the mean reduction
was 51.0% in the motor tic scores, 67.1% in the vocal tic
scores, and 70.0% in the total YGTSSs.
The mean dose of aripiprazole during treatment was
2.84  0.48 mg/day, and the maximal dose was
3.23  0.88 mg/day. The dose was unrelated to body
weight. In addition, YGTSSs at baseline showed no signifi-
cant difference among the transient TD (29.74  7.68),Table 2 Analysis of the YGTSS in motor tic, vocal tic, and tota
Motor tic score
b* (SE
y
) p b* (SE
y
)
Week 0z Reference Referen
Week 2z 3.48 (0.64) <0.01 2.98 (
Week 6z 4.62 (0.77) <0.01 4.18 (
Week 10z 6.58 (0.83) <0.01 5.32 (
Week 14z 6.21 (0.88) <0.01 6.22 (
The data are adjusted for gender, age, type of tic, comorbidity of AD
ADHD Z attention deficit hyperactivity disorder; YGTSS Z Yale Glob
* b-coefficient.
y Standard error (SE).
z Compared with the baseline score.chronic TD (30.00  9.90), and TS (34.33  6.85) groups.
The YGTSSs at week 14 of the transient TD, chronic TD, and
TS groups were 8.35  8.37, 8.50  2.12, and 10.39  9.14,
respectively. The degree of improvement was not signifi-
cantly different in transient TD, chronic TD, and TS.
Most patients tolerated aripiprazole well, and no drug-
related EPS was noted in this study. The adverse effects are
listed in Table 3. Sedation and increased appetite were the
most common adverse effects reported by the patients.
Sedation was usually mild without influencing daily life and
improved with time or after decreasing dose. Two patients
became temperamental, and three patients became better
tempered. Other adverse effects were usually mild and
improved later or after the discontinuation of medications.
There was a slight increase in average individual body
weight between baseline and end point, from 32.7  14.9
to 33.7  14.8 kg (þ1.0 kg, p < 0.05).
4. Discussion
There are two major pharmacotherapies for TDd
antipsychotic and nonantipsychotic medications. Although
typical antipsychotic medications, such as haloperidol and
pimozide, appear to have higher potency for reducing
symptoms, they are associated with the risk of severe and
unacceptable adverse effects.5 Sulpiride, a selective
dopamine D2 antagonist, is also effective for treatment of
TS and chronic TD. According to our previous study, the
severity rate decreased by 49% in motor tic scores, 64% in
vocal tic scores, and 59% in total YGTSSs.7 However, the
half-life of sulpiride is short. Therefore, it needs to be
taken two times every day, but some patients do not follow
this requirement. Atypical antipsychotics, such as risperi-
done, olanzapine, ziprasidone, quetiapine, and clozapine,
have serotonin-blocking effects, but variable D2-blocking
properties with fewer neurological adverse effects. They
can reduce symptoms by approximately 35e50%. However,
weight gain and metabolic complications, such as hyper-
prolactinemia and dyslipidemia, are worrisome con-
cerns.8e12 Among nonantipsychotic medications, clonidine,
an a-adrenergic agonist, is widely used and can reduce 26%
of symptoms. However, many clinicians are reluctant to use
it due to concerns regarding hypotension.13
In previous small case series, aripiprazole reduced total
YGTSSs by 44.3e56.0%. The improvements in the totall scores by the linear mixed model.
Vocal tic score Total YGTSS
p b* (SE
y
) p
ce Reference
0.60) <0.01 13.24 (1.24) <0.01
0.76) <0.01 17.15 (1.36) <0.01
0.85) <0.01 21.45 (1.42) <0.01
0.92) <0.01 22.16 (1.47) <0.01
HD, and drug dose.
al Tic Severity Score.
Table 3 Adverse effects reported by patients treated
with aripiprazole.
Adverse effect n (%)
Sedation 26 (32.1)
Increased appetite 18 (22.2)
Decreased appetite 5 (6.2)
Became quiet 5 (6.2)
Gastrointestinal upset 4 (4.9)
Somnambulism 3 (3.7)
Mood lability 2 (2.5)
Dizziness 2 (2.5)
Headache 1 (1.2)
Aripiprazole in treatment of tic disorder 51motor and vocal scores were 50.0e61.3% and 56.3e71.4%,
respectively.14e18 The results, which showed greater
responsiveness to aripiprazole in vocal tics than in motor
tics, were similar to our study. If we compare the TS group
and the chronic TD group in our study with our previous
study,7 the dramatic reduction of vocal tic scores in the
aripiprazole group was more apparent than the sulpiride
group by the 2nd week.
Some authors have suggested that aripiprazole has the
potential to treat irritability and aggression, which are the
common comorbidities of TD.19,20 In this study, three pa-
tients became better-tempered, whereas two became
temperamental after aripiprazole treatment. Because of
the lack of a placebo group, it is difficult to differentiate
the effects of drug from the nature course.
Furthermore, the dose of aripiprazole in TD was not
well-established in pediatric groups due to the limited
number of studies. The initial dose of aripiprazole in most
previous studies (4.5e20 mg/day) is higher than that of the
present study. Children and adolescents might be more
susceptible to dose-related side effects of aripiprazole,
because of the higher mean peak steady-state concentra-
tion and shorter time to required to reach maximum serum
concentration of aripiprazole.21 The use of a higher dosage
did result in an increasing incidence of adverse effects,
such as sedation (16.7e81.8%), blurred vision (9.0%), and
EPS (8.3e63.0%) in previous studies.14e18 Because the dose
was not related to body weight in our study, the specific
dose for aripiprazole in treatment of TD could not be
established. However, some patients were already
responding well to lower doses (2.5 mg/day). Therefore, we
suggest administering a lower dose initially and then slowly
increasing the dosage based on clinical response.
Patients are often involved in the dilemma of whether to
face the tic-related embarrassment or to bear the adverse
effects of the medicine, especially traditional antipsy-
chotics. In our study, no serious adverse effects such as EPS
were associated with aripiprazole. One-third of the pa-
tients encountered sedation, but this resolved with time or
decreasing doses. The degree of body weight gain in pa-
tients using aripiprazole was lower than those in patients
using other atypical antipsychotic medications,8,9 and part
of the body weight gain might be due to normal growth.22
Previous studies also supported no significant changes of
metabolic parameters, and even decreasing QTc interval
during aripiprazole treatment.19,23There were some limitations in our study. The natural
course of TD is fluctuating, and therefore, it is difficult to
differentiate the effects of the drug during the clinical
course without having a placebo group. Furthermore, the
rate of transient TD in our study was 65.4%; however, the
degree of improvement was not different in patients with
transient TD, chronic TD, and TS. Third, the severity of
infections in the patients was mild to moderate. Therefore,
the effectiveness of treatment in severe TDs requires
further study.
In conclusion, aripiprazole is effective for the short-term
treatment of TD, especially vocal tics, with few adverse
effects. However, further double-blind trials against pla-
cebo or other medications are needed to verify the role of
aripiprazole in the pharmacotherapy of TD.
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